-
Patent Agency Ranking
公开(公告)号：US10793601B2
公开(公告)日：2020-10-06
申请号：US16095603
申请日：2017-04-28
Applicant: National University of Singapore , The Brigham and Women's Hospital, Inc. , Agency for Science, Technology and Research
Inventor： Bee Hui Liu , Daniel Geoffrey Tenen , Li Chai , Cheng San Brian Chia , Anders Poulsen
Abstract: Isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 (RBBp4) and block the Spalt-Like Transcription Factor 4 (SALL4)-RBBp4 interaction are described. Methods of inhibiting binding of SALL4 to RBBp4 and methods of treating a subject having a disorder mediated by a dysregulation of SALL4 are also described.
-
公开(公告)号：US20160038567A1
公开(公告)日：2016-02-11
申请号：US14675675
申请日：2015-03-31
Applicant: Agency for Science, Technology and Research
Inventor： Christopher John BROWN , Cheng San Brian Chia
IPC: A61K38/17
CPC classification number: A61K38/1709 , A61K38/00 , C07K7/08 , C07K14/4705 , C07K2319/10
Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
-
公开(公告)号：US20190218253A1
公开(公告)日：2019-07-18
申请号：US16095603
申请日：2017-04-28
Applicant: National University of Singapore , The Brigham and Women's Hospital, Inc. , Agency for Science, Technology and Research
Inventor： Bee Hui Liu , Daniel Geoffrey Tenen , Li Chai , Cheng San Brian Chia , Anders Poulsen
Abstract: The present invention provides, in certain embodiments, isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 RBBp4 such that, the binding blocks the SALL4-RBBp4 interaction. Methods of inhibiting binding of SALL4 with RBBp4 and methods for treating a subject having a disorder mediated by a dysregulation of SALL4 are also provided.
-
公开(公告)号：US20190071416A1
公开(公告)日：2019-03-07
申请号：US15767129
申请日：2016-10-10
Applicant: Agency For Science, Technology and Research
Inventor： Klement Jihao Foo , Anders Poulsen , Thomas Hugo Keller , Si Si Liew , Cheng San Brian Chia , Jin Yan Melgious Ang , Chuhul Huang
IPC: C07D401/06 , A61P35/00 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D405/14
Abstract: Compounds For Inhibition Of Cancer and Epigenesis. The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.
-
公开(公告)号：US09533023B2
公开(公告)日：2017-01-03
申请号：US14675675
申请日：2015-03-31
Applicant: Agency for Science, Technology and Research
Inventor： Christopher John Brown , Cheng San Brian Chia
CPC classification number: A61K38/1709 , A61K38/00 , C07K7/08 , C07K14/4705 , C07K2319/10
Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
Abstract translation: 本发明涉及修饰的eIF4G1肽，其用途和包含经修饰的eIF4G1肽的药物组合物。
-
-
-
-
Search Results
5
records
(took 0.024 seconds)
